LAG3 and cancer: Notably, the most commonly targeted checkpoints for cancer immunotherapy, such as PDCD1, CTLA4, LAG3, and TIGHT exhibited a significantly higher expression in cluster 1 compared to cluster 2 (Figure 5F).